The role of toll-like receptors in B-cell development and immunopathogenesis of common variable immunodeficiency

References

Papers of special note have been highlighted as

• of interest

•• of considerable interest

• Aghamohammadi A, Abolhassani H, Latif A, et al. Long-term evaluation of a historical cohort of Iranian common variable immunodeficiency patients. Expert Rev Clin Immunol. 2014;10(10):1405–1417.
   PubMed Web of Science ®Google Scholar
• Bayry J, Hermine O, Webster DA, et al. Common variable immunodeficiency: the immune system in chaos. Trends Mol Med. 2005;11(8):370–376.
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.
   PubMed Web of Science ®Google Scholar
• Mouillot G, Carmagnat M, Gerard L, et al. B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol. 2010;30(5):746–755.
   PubMed Web of Science ®Google Scholar
• Resnick ES, Cunningham-Rundles C. The many faces of the clinical picture of common variable immune deficiency. Curr Opin Allergy Clin Immunol. 2012;12(6):595–601.
   PubMed Web of Science ®Google Scholar
• Taraldsrud E, Fevang B, Aukrust P, et al. Common variable immunodeficiency revisited: normal generation of naturally occurring dendritic cells that respond to Toll-like receptors 7 and 9. Clin Exp Immunol. 2014;175(3):439–448.
   PubMed Web of Science ®Google Scholar
• Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–286.
   PubMed Web of Science ®Google Scholar
• Notarangelo LD, Fischer A, Geha RS, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124(6):1161–1178.
   PubMed Web of Science ®Google Scholar
• Agematsu K, Futatani T, Hokibara S, et al. Absence of memory B cells in patients with common variable immunodeficiency. Clin Immunol. 2002;103(1):34–42.
   PubMed Web of Science ®Google Scholar
• Warnatz K, Denz A, Drager R, et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002;99(5):1544–1551.
   PubMed Web of Science ®Google Scholar
• Taubenheim N, von Hornung M, Durandy A, et al. Defined blocks in terminal plasma cell differentiation of common variable immunodeficiency patients. J Immunol. 2005;175(8):5498–5503.
   PubMed Web of Science ®Google Scholar
• Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5:162.
   PubMed Web of Science ®Google Scholar
• Grimbacher B, Hutloff A, Schlesier M, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol. 2003;4(3):261–268.
   PubMed Web of Science ®Google Scholar
• Warnatz K, Salzer U, Rizzi M, et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A. 2009;106(33):13945–13950.
   PubMed Web of Science ®Google Scholar
• van Zelm MC, Reisli I, van der Burg M, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006;354(18):1901–1912.
   PubMed Web of Science ®Google Scholar
• van Zelm MC, Smet J, Adams B, et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest. 2010;120(4): 1265–1274.
   PubMed Web of Science ®Google Scholar
• Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120(1):214–222.
   PubMed Web of Science ®Google Scholar
• Abolhassani H, Wang N, Aghamohammadi A, et al. A hypomorphic recombination-activating gene 1 (RAG1) mutation resulting in a phenotype resembling common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(6):1375–1380.
   PubMed Web of Science ®Google Scholar
• Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005;37(8):820–828.
   PubMed Web of Science ®Google Scholar
• Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37(8):829–834.
   PubMed Web of Science ®Google Scholar
• Goldacker S, Warnatz K. Tackling the heterogeneity of CVID. Curr Opin Allergy Clin Immunol. 2005;5(6):504–509.
   PubMed Web of Science ®Google Scholar
• Ferrer JM, Iglesias J, Hernandez M, et al. Alterations in interleukin secretion (IL-2 and IL-4) by CD4 and CD4 CD45RO cells from common variable immunodeficiency (CVI) patients. Clin Exp Immunol. 1995;102(2):286–289.
   PubMed Web of Science ®Google Scholar
• Iglesias J, Matamoros N, Raga S, et al. CD95 expression and function on lymphocyte subpopulations in common variable immunodeficiency (CVID); related to increased apoptosis. Clin Exp Immunol. 1999;117(1):138–146.
   PubMed Web of Science ®Google Scholar
• North ME, Webster AD, Farrant J. Defects in proliferative responses of T cells from patients with common variable immunodeficiency on direct activation of protein kinase C. Clin Exp Immunol. 1991;85(2):198–201.
   PubMed Web of Science ®Google Scholar
• Martinez-Pomar N, Raga S, Ferrer J, et al. Elevated serum interleukin (IL)-12p40 levels in common variable immunodeficiency disease and decreased peripheral blood dendritic cells: analysis of IL-12p40 and interferon-gamma gene. Clin Exp Immunol. 2006;144(2):233–238.
   PubMed Web of Science ®Google Scholar
• Marron TU, Yu JE, Cunningham-Rundles C. Toll-like receptor function in primary B cell defects. Front Biosci (Elite Ed). 2012;4:1853–1863.
   PubMedGoogle Scholar
• Netea MG, van de Veerdonk FL, van der Meer JW. Primary immunodeficiencies of pattern recognition receptors. J Intern Med. 2012;272(6):517–527.
   PubMed Web of Science ®Google Scholar
• Casanova JL, Fieschi C, Zhang SY, et al. Revisiting human primary immunodeficiencies. J Intern Med. 2008;264(2):115–127.
   PubMed Web of Science ®Google Scholar
• Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol. 2011;29:447–491.
   PubMed Web of Science ®Google Scholar
• Netea MG, Wijmenga C, O’Neill LA. Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol. 2012;13(6):535–542.
   PubMed Web of Science ®Google Scholar
• Medvedev AE. Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer. J Interferon Cytokine Res. 2013;33(9):467–484.
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C, Radigan L, Knight AK, et al. TLR9 activation is defective in common variable immune deficiency. J Immunol. 2006;176(3):1978–1987.
   PubMed Web of Science ®Google Scholar

•• The first article that showed altered CVID B-cells responses to TLR9 stimulation consist of impaired upregulation of CD86 and AID mRNA, B-cell proliferation, Ig production and IL-6 and IL-10 secretion after stimulation of CpG DNA with and without BCR engagement.

• Maglione PJ, Simchoni N, Cunningham-Rundles C. Toll-like receptor signaling in primary immune deficiencies. N Y Acad Sci. 2015;1356(1):1–21.
   Google Scholar
• Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637–650.
   PubMed Web of Science ®Google Scholar
• Broz P, Monack DM. Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol. 2013;13(8):551–565.
   PubMed Web of Science ®Google Scholar
• Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010;(2010):Article ID 672395:21.
   Web of Science ®Google Scholar
• Netea MG, van der Graaf C, Van der Meer JW, et al. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol. 2004;75(5):749–755.
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7(5):353–364.
   PubMed Web of Science ®Google Scholar
• Sato S, Nomura F, Kawai T, et al. Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol. 2000;165(12):7096–7101.
   PubMed Web of Science ®Google Scholar
• Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6(8):769–776.
   PubMed Web of Science ®Google Scholar
• Dennehy KM, Ferwerda G, Faro-Trindade I, et al. Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol. 2008;38(2):500–506.
   PubMed Web of Science ®Google Scholar
• Gringhuis SI, den Dunnen J, Litjens M, et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nat Immunol. 2009;10(2):203–213.
   PubMed Web of Science ®Google Scholar
• Carpenter S, O’Neill LA. How important are Toll-like receptors for antimicrobial responses? Cell Microbiol. 2007;9(8):1891–1901.
   PubMed Web of Science ®Google Scholar
• Bochud PY, Bochud M, Telenti A, et al. Innate immunogenetics: a tool for exploring new frontiers of host defence. Lancet Infect Dis. 2007;7(8):531–542.
   PubMed Web of Science ®Google Scholar
• Chapman SJ, Hill AV. Human genetic susceptibility to infectious disease. Nat Rev Genet. 2012;13(3):175–188.
   PubMed Web of Science ®Google Scholar
• Hennessy EJ, Parker AE, O’Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9(4):293–307.
   PubMed Web of Science ®Google Scholar
• Booth J, Wilson H, Jimbo S, et al. Modulation of B cell responses by Toll-like receptors. Cell Tissue Res. 2011;343(1):131–140.
   PubMed Web of Science ®Google Scholar
• Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol. 2006;36(4):810–816.
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003;101(11):4500–4504.
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Manz RA. Tolls for B cells. Eur J Immunol. 2006;36(4):798–801.
   PubMed Web of Science ®Google Scholar
• Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168(9):4531–4537.
   PubMed Web of Science ®Google Scholar
• Ganley-Leal LM, Liang Y, Jagannathan-Bogdan M, et al. Differential regulation of TLR4 expression in human B cells and monocytes. Mol Immunol. 2010;48(1–3):82–88.
   PubMed Web of Science ®Google Scholar
• Xu W, Santini PA, Matthews AJ, et al. Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J Immunol. 2008;181(1):276–287.
   PubMed Web of Science ®Google Scholar
• Ganley-Leal LM, Liu X, Wetzler LM. Toll-like receptor 2-mediated human B cell differentiation. Clin Immunol. 2006;120(3):272–284.
   PubMed Web of Science ®Google Scholar
• Mansson A, Adner M, Hockerfelt U, et al. A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. Immunology. 2006;118(4):539–548.
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding I, Doster A, Schiller M, et al. TLR9-activating DNA up-regulates ZAP70 via sustained PKB induction in IgM+ B cells. J Immunol. 2008;181(12):8267–8277.
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding IB, Wagner M, Hornung V, et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol. 2005;174(7):4043–4050.
   PubMed Web of Science ®Google Scholar
• Poeck H, Wagner M, Battiany J, et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood. 2004;103(8):3058–3064.
   PubMed Web of Science ®Google Scholar
• He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol. 2004;173(7):4479–4491.
   PubMed Web of Science ®Google Scholar
• Huggins J, Pellegrin T, Felgar RE, et al. CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells. Blood. 2007;109(4):1611–1619.
   PubMed Web of Science ®Google Scholar
• Jiang W, Lederman MM, Harding CV, et al. TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol. 2007;37(8):2205–2213.
   PubMed Web of Science ®Google Scholar
• Cognasse F, Hamzeh-Cognasse H, Lafarge S, et al. Identification of two subpopulations of purified human blood B cells, CD27- CD23+ and CD27high CD80+, that strongly express cell surface Toll-like receptor 9 and secrete high levels of interleukin-6. Immunology. 2008;125(3):430–437.
   PubMed Web of Science ®Google Scholar
• Dasari P, Nicholson IC, Hodge G, et al. Expression of toll-like receptors on B lymphocytes. Cell Immunol. 2005;236(1–2):140–145.
   PubMed Web of Science ®Google Scholar
• Eaton-Bassiri A, Dillon SB, Cunningham M, et al. Toll-like receptor 9 can be expressed at the cell surface of distinct populations of tonsils and human peripheral blood mononuclear cells. Infect Immun. 2004;72(12):7202–7211.
   PubMed Web of Science ®Google Scholar
• Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6(11):823–835.
   PubMed Web of Science ®Google Scholar
• Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, et al. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood. 2008;112(6):2205–2213.
   PubMed Web of Science ®Google Scholar
• Lampropoulou V, Hoehlig K, Roch T, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol. 2008;180(7):4763–4773.
   PubMed Web of Science ®Google Scholar
• Hasan M, Lopez-Herrera G, Blomberg KE, et al. Defective Toll-like receptor 9-mediated cytokine production in B cells from Bruton’s tyrosine kinase-deficient mice. Immunology. 2008;123(2):239–249.
   PubMed Web of Science ®Google Scholar
• Lenert P, Brummel R, Field EH, et al. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol. 2005;25(1):29–40.
   PubMed Web of Science ®Google Scholar
• Lee KG, Xu S, Wong ET, et al. Bruton’s tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells. J Biol Chem. 2008;283(17):11189–11198.
   PubMed Web of Science ®Google Scholar
• Schmidt NW, Thieu VT, Mann BA, et al. Bruton’s tyrosine kinase is required for TLR-induced IL-10 production. J Immunol. 2006;177(10):7203–7210.
   PubMed Web of Science ®Google Scholar
• Dil N, Marshall AJ. Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation. Mol Immunol. 2009;46(10):1970–1978.
   PubMed Web of Science ®Google Scholar
• Barr TA, Brown S, Ryan G, et al. TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. Eur J Immunol. 2007;37(11):3040–3053.
   PubMed Web of Science ®Google Scholar
• Ng LG, Ng CH, Woehl B, et al. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur J Immunol. 2006;36(7):1837–1846.
   PubMed Web of Science ®Google Scholar
• Sun CM, Deriaud E, Leclerc C, et al. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity. 2005;22(4):467–477.
   PubMed Web of Science ®Google Scholar
• Zhang X, Deriaud E, Jiao X, et al. Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J Exp Med. 2007;204(5):1107–1118.
   PubMed Web of Science ®Google Scholar
• Hanten JA, Vasilakos JP, Riter CL, et al. Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol. 2008;9:39.
   PubMed Web of Science ®Google Scholar
• Glaum MC, Narula S, Song D, et al. Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production. J Allergy Clin Immunol. 2009;123(1):224–230 e4.
   PubMed Web of Science ®Google Scholar
• Malaspina A, Moir S, DiPoto AC, et al. CpG oligonucleotides enhance proliferative and effector responses of B Cells in HIV-infected individuals. J Immunol. 2008;181(2):1199–1206.
   PubMed Web of Science ®Google Scholar
• Wagner M, Poeck H, Jahrsdoerfer B, et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol. 2004;172(2):954–963.
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding I, Jego G. Toll-like receptors–sentries in the B-cell response. Immunology. 2009;128(3):311–323.
   PubMed Web of Science ®Google Scholar
• Choe J, Choi YS. IL-10 interrupts memory B cell expansion in the germinal center by inducing differentiation into plasma cells. Eur J Immunol. 1998;28(2):508–515.
   PubMed Web of Science ®Google Scholar
• Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol. 2008;26:133–169.
   PubMed Web of Science ®Google Scholar
• Genestier L, Taillardet M, Mondiere P, et al. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol. 2007;178(12):7779–7786.
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck JP, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19(2):225–234.
   PubMed Web of Science ®Google Scholar
• Chen-Kiang S. Regulation of terminal differentiation of human B-cells by IL-6. Curr Top Microbiol Immunol. 1995;194:189–198.
   PubMedGoogle Scholar
• Su TT, Guo B, Wei B, et al. Signaling in transitional type 2 B cells is critical for peripheral B-cell development. Immunol Rev. 2004;197:161–178.
   PubMed Web of Science ®Google Scholar
• Hayashi EA, Akira S, Nobrega A. Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2. J Immunol. 2005;174(11):6639–6647.
   PubMed Web of Science ®Google Scholar
• Wei B, Su TT, Dalwadi H, et al. Resident enteric microbiota and CD8+ T cells shape the abundance of marginal zone B cells. Eur J Immunol. 2008;38(12):3411–3425.
   PubMed Web of Science ®Google Scholar
• Richard K, Pierce SK, Song W. The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo. J Immunol. 2008;181(3):1746–1752.
   PubMed Web of Science ®Google Scholar
• Zapata JM, Llobet D, Krajewska M, et al. Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood. 2009;113(19):4595–4603.
   PubMed Web of Science ®Google Scholar
• Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006;20(6):1138–1144.
   PubMed Web of Science ®Google Scholar
• Jego G, Bataille R, Geffroy-Luseau A, et al. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia. 2006;20(6):1130–1137.
   PubMed Web of Science ®Google Scholar
• Chaudhuri J, Alt FW. Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat Rev Immunol. 2004;4(7):541–552.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695–703.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 2006;124(4):849–863.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401–409.
   PubMed Web of Science ®Google Scholar
• Lutzker S, Rothman P, Pollock R, et al. Mitogen- and IL-4-regulated expression of germ-line Ig gamma 2b transcripts: evidence for directed heavy chain class switching. Cell. 1988;53(2):177–184.
   PubMed Web of Science ®Google Scholar
• Mandler R, Finkelman FD, Levine AD, et al. IL-4 induction of IgE class switching by lipopolysaccharide-activated murine B cells occurs predominantly through sequential switching. J Immunol. 1993;150(2):407–418.
   PubMed Web of Science ®Google Scholar
• Capolunghi F, Cascioli S, Giorda E, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol. 2008;180(2):800–808.
   PubMed Web of Science ®Google Scholar
• Severinson E, Fernandez C, Stavnezer J. Induction of germ-line immunoglobulin heavy chain transcripts by mitogens and interleukins prior to switch recombination. Eur J Immunol. 1990;20(5):1079–1084.
   PubMed Web of Science ®Google Scholar
• He B, Xu W, Santini PA, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity. 2007;26(6):812–826.
   PubMed Web of Science ®Google Scholar
• Lin L, Gerth AJ, Peng SL. CpG DNA redirects class-switching towards “Th1-like” Ig isotype production via TLR9 and MyD88. Eur J Immunol. 2004;34(5):1483–1487.
   PubMed Web of Science ®Google Scholar
• Heer AK, Shamshiev A, Donda A, et al. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol. 2007;178(4):2182–2191.
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Bernasconi N, Traggiai E, et al. Understanding and making use of human memory B cells. Immunol Rev. 2006;211:303–309.
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine. 2007;25(30):5467–5484.
   PubMed Web of Science ®Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol. 2007;5(7):505–517.
   PubMed Web of Science ®Google Scholar
• Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc. 2007;4(3):289–294.
   PubMedGoogle Scholar
• Rubtsov AV, Swanson CL, Troy S, et al. TLR agonists promote marginal zone B cell activation and facilitate T-dependent IgM responses. J Immunol. 2008;180(6):3882–3888.
   PubMed Web of Science ®Google Scholar
• Khan AQ, Shen Y, Wu ZQ, et al. Endogenous pro- and anti-inflammatory cytokines differentially regulate an in vivo humoral response to Streptococcus pneumoniae. Infect Immun. 2002;70(2):749–761.
   PubMed Web of Science ®Google Scholar
• Won WJ, Bachmann MF, Kearney JF. CD36 is differentially expressed on B cell subsets during development and in responses to antigen. J Immunol. 2008;180(1):230–237.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675–680.
   PubMed Web of Science ®Google Scholar
• Guay HM, Andreyeva TA, Garcea RL, et al. MyD88 is required for the formation of long-term humoral immunity to virus infection. J Immunol. 2007;178(8):5124–5131.
   PubMed Web of Science ®Google Scholar
• Koyama S, Ishii KJ, Kumar H, et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol. 2007;179(7):4711–4720.
   PubMed Web of Science ®Google Scholar
• Gavin AL, Hoebe K, Duong B, et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science. 2006;314(5807):1936–1938.
   PubMed Web of Science ®Google Scholar
• Nemazee D, Gavin A, Hoebe K, et al. Immunology: toll-like receptors and antibody responses. Nature. 2006;441(7091):E4. discussion E4
   PubMed Web of Science ®Google Scholar
• Alugupalli KR, Akira S, Lien E, et al. MyD88- and Bruton’s tyrosine kinase-mediated signals are essential for T cell-independent pathogen-specific IgM responses. J Immunol. 2007;178(6):3740–3749.
   PubMed Web of Science ®Google Scholar
• Wooten RM, Ma Y, Yoder RA, et al. Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol. 2002;168(1):348–355.
   PubMed Web of Science ®Google Scholar
• Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore). 2010;89(6):403–425.
   PubMed Web of Science ®Google Scholar
• Ku CL, von Bernuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med. 2007;204(10):2407–2422.
   PubMed Web of Science ®Google Scholar
• Browne EP. Toll-like receptor 7 controls the anti-retroviral germinal center response. PLoS Pathog. 2011;7(10):e1002293.
   PubMed Web of Science ®Google Scholar
• Clingan JM, Matloubian M. B Cell-intrinsic TLR7 signaling is required for optimal B cell responses during chronic viral infection. J Immunol. 2013;191(2):810–818.
   PubMed Web of Science ®Google Scholar
• Walsh KB, Teijaro JR, Zuniga EI, et al. Toll-like receptor 7 is required for effective adaptive immune responses that prevent persistent virus infection. Cell Host Microbe. 2012;11(6):643–653.
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramon S, Radigan L, Yu JE, et al. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin Immunol. 2008;128(3):314–321.
   PubMed Web of Science ®Google Scholar
• Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85.
   PubMed Web of Science ®Google Scholar
• Branda RF, Moore AL, Mathews L, et al. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol. 1993;45(10):2037–2043.
   PubMed Web of Science ®Google Scholar
• Branda RF, Moore AL, Lafayette AR, et al. Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J Lab Clin Med. 1996;128(3):329–338.
   PubMed Web of Science ®Google Scholar
• Branda RF, Moore AL, Hong R, et al. B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol. 1996;79(2):115–121.
   PubMedGoogle Scholar

• Provides evidences for CVID B-cell defects after stimulation with an antisense oligomer to the rev gene of HIV-1 that some years later, after the recognition of TLR9, generates the hypothesis of the role of TLRs in immunopathogenesis of CVID.

• Escobar D, Pons J, Clemente A, et al. Defective B cell response to TLR9 ligand (CpG-ODN), Streptococcus pneumoniae and Haemophilus influenzae extracts in common variable immunodeficiency patients. Cell Immunol. 2010;262(2):105–111.
   PubMed Web of Science ®Google Scholar

• Indicates disability of B cells of CVID patients in response to different natural and synthetic ligands of TLRs.

• Yu JE, Knight AK, Radigan L, et al. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. J Allergy Clin Immunol. 2009;124(2):349–356, 356 e1–3.
   PubMed Web of Science ®Google Scholar

• Shows multiple defects in B cells of CVID patients in response to TLR7 and TLR9 stimulation, but the cytokine secretion by PBMCs is normal.

• Trujillo CM, Muskus C, Arango J, et al. Quantitative and functional evaluation of innate immune responses in patients with common variable immunodeficiency. J Investig Allergol Clin Immunol. 2011;21(3):207–215.
   PubMed Web of Science ®Google Scholar

• Evaluates the responses of innate immune cells of PBMCs of CVID patients to agonists of TLR2, TLR4 and TLR9 and show no change in cytokine production of patients.

• Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194(6):863–869.
   PubMed Web of Science ®Google Scholar
• Dorner M, Brandt S, Tinguely M, et al. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology. 2009;128(4):573–579.
   PubMed Web of Science ®Google Scholar
• Douagi I, Gujer C, Sundling C, et al. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol. 2009;182(4):1991–2001.
   PubMed Web of Science ®Google Scholar
• Braun D, Caramalho I, Demengeot J. IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol. 2002;14(4):411–419.
   PubMed Web of Science ®Google Scholar
• Cerutti A, Qiao X, He B. Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching. Immunol Cell Biol. 2005;83(5):554–562.
   PubMed Web of Science ®Google Scholar
• Giordani L, Sanchez M, Libri I, et al. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production. J Leukoc Biol. 2009;86(2):261–271.
   PubMed Web of Science ®Google Scholar
• Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood. 2004;104(8):2441–2443.
   PubMed Web of Science ®Google Scholar
• Nourizadeh M, Aghamohammadi A, Moazzeni SM, et al. Altered dendritic cell function in response to sera of common variable immunodeficiency patients. Inflamm Res. 2007;56(12):527–532.
   PubMed Web of Science ®Google Scholar
• Scott-Taylor TH, Green MR, Eren E, et al. Monocyte derived dendritic cell responses in common variable immunodeficiency. Clin Exp Immunol. 2004;138(3):484–490.
   PubMed Web of Science ®Google Scholar
• Scott-Taylor TH, Green MR, Raeiszadeh M, et al. Defective maturation of dendritic cells in common variable immunodeficiency. Clin Exp Immunol. 2006;145(3):420–427.
   PubMed Web of Science ®Google Scholar
• Yu JE, Zhang L, Radigan L, et al. TLR-mediated B cell defects and IFN-alpha in common variable immunodeficiency. J Clin Immunol. 2012;32(1):50–60.
   PubMed Web of Science ®Google Scholar

• Demonstrates the role of INF-alpha on function and maturation of CVID B cells accompanying TLR7 and TLR9 stimulation.

• Brown KN, Wijewardana V, Liu X, et al. Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathog. 2009;5(5):e1000413.
   PubMed Web of Science ®Google Scholar
• Swiecki M, Wang Y, Vermi W, et al. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med. 2011;208(12):2367–2374.
   PubMed Web of Science ®Google Scholar
• Abolhassani H, Amirkashani D, Parvaneh N, et al. Autoimmune phenotype in patients with common variable immunodeficiency. J Investig Allergol Clin Immunol. 2013;23(5):323–329.
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C. Common variable immunodeficiency. Curr Allergy Asthma Rep. 2001;1(5):421–429.
   PubMedGoogle Scholar
• Isnardi I, Ng YS, Srdanovic I, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity. 2008;29(5):746–757.
   PubMed Web of Science ®Google Scholar
• Visentini M, Conti V, Cagliuso M, et al. Regression of systemic lupus erythematosus after development of an acquired toll-like receptor signaling defect and antibody deficiency. Arthritis Rheum. 2009;60(9):2767–2771.
   PubMed Web of Science ®Google Scholar
• Ko J, Radigan L, Cunningham-Rundles C. Immune competence and switched memory B cells in common variable immunodeficiency. Clin Immunol. 2005;116(1):37–41.
   PubMed Web of Science ®Google Scholar
• Alachkar H, Taubenheim N, Haeney MR, et al. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol. 2006;120(3):310–318.
   PubMed Web of Science ®Google Scholar
• Detkova D, de Gracia J, Lopes-da-Silva S, et al. Common variable immunodeficiency: association between memory B cells and lung diseases. Chest. 2007;131(6):1883–1889.
   PubMed Web of Science ®Google Scholar
• Vodjgani M, Aghamohammadi A, Samadi M, et al. Analysis of class-switched memory B cells in patients with common variable immunodeficiency and its clinical implications. J Investig Allergol Clin Immunol. 2007;17(5):321–328.
   PubMed Web of Science ®Google Scholar
• Borte S, Pan-Hammarstrom Q, Liu C, et al. Interleukin-21 restores immunoglobulin production ex vivo in patients with common variable immunodeficiency and selective IgA deficiency. Blood. 2009;114(19):4089–4098.
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev. 2009;61(2):177–197.
   PubMed Web of Science ®Google Scholar
• Hedayat M, Netea MG, Rezaei N. Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect Dis. 2011;11(9):702–712.
   PubMed Web of Science ®Google Scholar
• Gooshe M, Aleyasin AR, Abdolghaffari AH, et al. Toll like receptors: a new hope on the horizon to treat multiple sclerosis. Expert Rev Clin Immunol. 2014;10(10):1277–1279.
   PubMed Web of Science ®Google Scholar
• Aryan Z, Holgate ST, Radzioch D, et al. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol. 2014;164(1):46–63.
   PubMed Web of Science ®Google Scholar
• Aalaei-andabili SH, Rezaei N. Toll like receptor (TLR)-induced differential expression of microRNAs (MiRs) promotes proper immune response against infections: a systematic review. J Infect. 2013;67(4):251–264.
   PubMed Web of Science ®Google Scholar
• Harsini S, Beigy M, Akhavan-Sabbagh M, et al. Toll-like receptors in lymphoid malignancies: double-edged sword. Crit Rev Oncol Hematol. 2014;89(2):262–283.
   PubMed Web of Science ®Google Scholar
• Indrevaer RL, Holm KL, Aukrust P, et al. Retinoic acid improves defective TLR9/RP105-induced immune responses in common variable immunodeficiency-derived B cells. J Immunol. 2013;191(7):3624–3633.
   PubMed Web of Science ®Google Scholar
• Baldridge JR, McGowan P, Evans JT, et al. Taking a Toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther. 2004;4(7):1129–1138.
   PubMed Web of Science ®Google Scholar